Expertise in
5
conditions

Goran U. Carlsson

Goeteborg, O, SE 
Expertise in
5
conditions
Goeteborg, O, SE 

Overview

Goran Carlsson practices practicing medicine in Goeteborg, Sweden.

Mr. Carlsson is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Severe Congenital Neutropenia, Agranulocytosis, Chronic Familial Neutropenia, and Colorectal Cancer.

He is actively involved in clinical research, co-authoring 34 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Goeteborg, O, Sweden
Other Locations
Stockholm, AB, Sweden
Solna, AB, Sweden

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Neoadjuvant Chemotherapy Versus Standard Treatment in Patients With Locally Advanced Colon Cancer
Neoadjuvant Chemotherapy Versus Standard Treatment in Patients With Locally Advanced Colon Cancer
Enrollment Status: Completed
Publish Date: August 21, 2026
Intervention Type: Drug
Study Drugs: Capecitabine, Oxaliplatin
Study Phase: Phase 3
An Open-label, Multiple-site, Phase I/II Dose Cohort Trial of [6R] 5,10-Methylene Tetrahydrofolate (Modufolin®) in Combination With a Fixed Dose of 5-Fluorouracil (5-FU) Alone or Together With a Fixed Dose of Oxaliplatin or Irinotecan in Patients With Stage IV Colorectal Cancer
An Open-label, Multiple-site, Phase I/II Dose Cohort Trial of [6R] 5,10-Methylene Tetrahydrofolate (Modufolin®) in Combination With a Fixed Dose of 5-Fluorouracil (5-FU) Alone or Together With a Fixed Dose of Oxaliplatin or Irinotecan in Patients With Stage IV Colorectal Cancer
Enrollment Status: Completed
Publish Date: September 09, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

34 Total Publications

Deoxyuridine as a surrogate marker of thymidylate synthase inhibition contributes to a multivariable model predicting 5-FU/LV response in metastatic colorectal cancer.
Deoxyuridine as a surrogate marker of thymidylate synthase inhibition contributes to a multivariable model predicting 5-FU/LV response in metastatic colorectal cancer.
Journal: Cancer treatment and research communications
Published: July 21, 2025

Frequently Asked Questions about Goran U. Carlsson

Is Goran U. Carlsson a top-rated expert for Severe Congenital Neutropenia?

MediFind is an objective health platform that identifies experts based on real-world data. Goran U. Carlsson is classified as an Distinguished expert for Severe Congenital Neutropenia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Goran U. Carlsson participate in research or clinical trials?

Yes. Goran U. Carlsson has published 34 articles and abstracts on conditions like Severe Congenital Neutropenia. You can view a list of Goran U. Carlsson's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Carlsson's expertise for a condition
ConditionClose
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile